These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 16368270

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
    Bioley G, Dousset C, Yeh A, Dupont B, Bhardwaj N, Mears G, Old LJ, Ayyoub M, Valmori D.
    Clin Cancer Res; 2009 Jul 01; 15(13):4467-74. PubMed ID: 19531622
    [Abstract] [Full Text] [Related]

  • 4. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.
    Bioley G, Guillaume P, Luescher I, Bhardwaj N, Mears G, Old L, Valmori D, Ayyoub M.
    J Immunother; 2009 Jul 01; 32(2):161-8. PubMed ID: 19238015
    [Abstract] [Full Text] [Related]

  • 5. Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.
    Garcia Casado J, Janda J, Wei J, Chapatte L, Colombetti S, Alves P, Ritter G, Ayyoub M, Valmori D, Chen W, Lévy F.
    Eur J Immunol; 2008 Jul 01; 38(7):1867-76. PubMed ID: 18546142
    [Abstract] [Full Text] [Related]

  • 6. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF.
    Sharma P, Bajorin DF, Jungbluth AA, Herr H, Old LJ, Gnjatic S.
    J Immunother; 2008 Jul 01; 31(9):849-57. PubMed ID: 18833002
    [Abstract] [Full Text] [Related]

  • 7. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.
    Korangy F, Ormandy LA, Bleck JS, Klempnauer J, Wilkens L, Manns MP, Greten TF.
    Clin Cancer Res; 2004 Jul 01; 10(13):4332-41. PubMed ID: 15240519
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen.
    Rodolfo M, Luksch R, Stockert E, Chen YT, Collini P, Ranzani T, Lombardo C, Dalerba P, Rivoltini L, Arienti F, Fossati-Bellani F, Old LJ, Parmiani G, Castelli C.
    Cancer Res; 2003 Oct 15; 63(20):6948-55. PubMed ID: 14583496
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
    Zarour HM, Maillere B, Brusic V, Coval K, Williams E, Pouvelle-Moratille S, Castelli F, Land S, Bennouna J, Logan T, Kirkwood JM.
    Cancer Res; 2002 Jan 01; 62(1):213-8. PubMed ID: 11782380
    [Abstract] [Full Text] [Related]

  • 12. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments.
    Held G, Matsuo M, Epel M, Gnjatic S, Ritter G, Lee SY, Tai TY, Cohen CJ, Old LJ, Pfreundschuh M, Reiter Y, Hoogenboom HR, Renner C.
    Eur J Immunol; 2004 Oct 01; 34(10):2919-29. PubMed ID: 15368308
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses.
    Gnjatic S, Atanackovic D, Jäger E, Matsuo M, Selvakumar A, Altorki NK, Maki RG, Dupont B, Ritter G, Chen YT, Knuth A, Old LJ.
    Proc Natl Acad Sci U S A; 2003 Jul 22; 100(15):8862-7. PubMed ID: 12853579
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines.
    Nishikawa H, Sato E, Briones G, Chen LM, Matsuo M, Nagata Y, Ritter G, Jäger E, Nomura H, Kondo S, Tawara I, Kato T, Shiku H, Old LJ, Galán JE, Gnjatic S.
    J Clin Invest; 2006 Jul 22; 116(7):1946-54. PubMed ID: 16794737
    [Abstract] [Full Text] [Related]

  • 18. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.
    Zarour HM, Storkus WJ, Brusic V, Williams E, Kirkwood JM.
    Cancer Res; 2000 Sep 01; 60(17):4946-52. PubMed ID: 10987311
    [Abstract] [Full Text] [Related]

  • 19. HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine.
    Bioley G, Guillaume P, Luescher I, Yeh A, Dupont B, Bhardwaj N, Mears G, Old LJ, Valmori D, Ayyoub M.
    Clin Cancer Res; 2009 Jan 01; 15(1):299-306. PubMed ID: 19118058
    [Abstract] [Full Text] [Related]

  • 20. Assessment of vaccine-induced CD4 T cell responses to the 119-143 immunodominant region of the tumor-specific antigen NY-ESO-1 using DRB1*0101 tetramers.
    Ayyoub M, Pignon P, Dojcinovic D, Raimbaud I, Old LJ, Luescher I, Valmori D.
    Clin Cancer Res; 2010 Sep 15; 16(18):4607-15. PubMed ID: 20670945
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.